Gamco Investors INC. ET AL Boosts Stock Holdings in NeoGenomics, Inc. $NEO

Gamco Investors INC. ET AL grew its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 525.0% during the 1st quarter, HoldingsChannel.com reports. The firm owned 100,000 shares of the medical research company’s stock after buying an additional 84,000 shares during the quarter. Gamco Investors INC. ET AL’s holdings in NeoGenomics were worth $742,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. First Light Asset Management LLC grew its stake in NeoGenomics by 1.1% in the 4th quarter. First Light Asset Management LLC now owns 10,035,063 shares of the medical research company’s stock valued at $118,012,000 after buying an additional 107,794 shares in the last quarter. First Trust Advisors LP bought a new stake in NeoGenomics during the 1st quarter valued at $45,725,000. Geode Capital Management LLC lifted its position in shares of NeoGenomics by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 3,176,644 shares of the medical research company’s stock worth $37,364,000 after acquiring an additional 44,733 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of NeoGenomics by 9.2% during the first quarter. Dimensional Fund Advisors LP now owns 2,674,335 shares of the medical research company’s stock worth $19,842,000 after acquiring an additional 225,588 shares in the last quarter. Finally, American Capital Management Inc. boosted its holdings in shares of NeoGenomics by 120.9% in the third quarter. American Capital Management Inc. now owns 2,345,263 shares of the medical research company’s stock worth $18,105,000 after acquiring an additional 1,283,390 shares during the period. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Lynn A. Tetrault sold 5,307 shares of the business’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $11.29, for a total transaction of $59,916.03. Following the completion of the transaction, the director directly owned 91,422 shares in the company, valued at $1,032,154.38. The trade was a 5.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.10% of the stock is currently owned by insiders.

NeoGenomics Stock Up 2.0%

Shares of NASDAQ:NEO opened at $13.40 on Wednesday. The firm has a fifty day moving average price of $12.39 and a two-hundred day moving average price of $10.65. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -17.40 and a beta of 1.74. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.42 and a quick ratio of 4.06. NeoGenomics, Inc. has a one year low of $4.72 and a one year high of $15.57.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.02. NeoGenomics had a negative net margin of 13.30% and a negative return on equity of 2.80%. The firm had revenue of $201.66 million for the quarter, compared to analysts’ expectations of $196.93 million. During the same quarter in the prior year, the firm posted $0.03 earnings per share. The business’s quarterly revenue was up 11.2% on a year-over-year basis. Analysts anticipate that NeoGenomics, Inc. will post -0.15 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Benchmark lifted their price target on NeoGenomics from $11.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, July 24th. TD Cowen reissued a “buy” rating on shares of NeoGenomics in a report on Wednesday, July 15th. Wall Street Zen upgraded NeoGenomics from a “hold” rating to a “buy” rating in a research note on Saturday, June 27th. Leerink Partners raised NeoGenomics from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $12.00 to $25.00 in a report on Wednesday, April 29th. Finally, Weiss Ratings upgraded NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 14th. Six analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $14.57.

Key Headlines Impacting NeoGenomics

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Q2 earnings beat estimates: NeoGenomics reported adjusted earnings of $0.05 per share, ahead of the $0.03 FactSet consensus. Revenue reached $201.66 million, exceeding analysts’ $196.93 million forecast. NeoGenomics Q2 adjusted EPS result
• Positive Sentiment: Full-year outlook increased: Management raised its fiscal 2026 revenue guidance to $802 million-$806 million, above the approximately $800.3 million analyst consensus. The higher outlook suggests continued demand and supports the positive investor reaction. NeoGenomics second-quarter results
• Positive Sentiment: Improving operating performance: Reports characterized the quarter as showing growth in both profit and revenue, with results described as outperforming expectations and the full-year outlook upgraded. NeoGenomics exceeds Q2 expectations
• Neutral Sentiment: Analyst stance remains cautious: NeoGenomics carries a consensus “Hold” rating, indicating that some investors may view the improved results and guidance as largely reflected in the stock’s recent gains. NeoGenomics consensus analyst rating
• Negative Sentiment: Profitability remains a concern: Despite the quarterly earnings beat, the company reported a negative net margin of 13.30% and negative return on equity of 2.80%, highlighting ongoing profitability risks.

NeoGenomics Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.